Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Amendment

21 May 2014 17:35

RNS Number : 7502H
GoldmanSachs International
21 May 2014
 

Amendment - due to the amendment of Equity and Derivative transactions, the disclosure made on 19 May for dealings on 15 May has been updated. Sections 2(a) and 2(b) have been updated.

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

(GS) GOLDMAN SACHS INTERNATIONAL

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

ASTRAZENECA PLC

(d) Date dealing undertaken:

15 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

YES - disclosed previously for PFIZER INC

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

USD 0.25 ordinary

Purchases

478,7205,521

47.2650 GBP521.0000 SEK

46.3450 GBP516.8859 SEK

USD 0.25 ordinary

Sales

541,5444,234

47.2650 GBP518.0000 SEK

46.4250 GBP513.5000 SEK

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

USD 0.25 ordinary

CFD

Reducing a long position

7,500

46.2204 GBP

USD 0.25 ordinary

CFD

Reducing a long position

5,329

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a long position

11,622

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a long position

30,000

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a long position

26,049

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a long position

2,000

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a short position

245

46.6998 GBP

USD 0.25 ordinary

CFD

Reducing a short position

184

46.6998 GBP

USD 0.25 ordinary

CFD

Reducing a short position

529

46.6998 GBP

USD 0.25 ordinary

CFD

Reducing a short position

748

46.6998 GBP

USD 0.25 ordinary

CFD

Reducing a long position

871

46.7683 GBP

USD 0.25 ordinary

CFD

Reducing a long position

2,929

46.7683 GBP

USD 0.25 ordinary

CFD

Reducing a long position

50,000

46.8725 GBP

USD 0.25 ordinary

CFD

Opening a short position

11,000

46.9343 GBP

USD 0.25 ordinary

CFD

Opening a short position

14

46.9499 GBP

USD 0.25 ordinary

CFD

Opening a short position

121

46.9499 GBP

USD 0.25 ordinary

CFD

Opening a long position

63,022

47.0760 GBP

USD 0.25 ordinary

CFD

Reducing a long position

1,548

47.2650 GBP

USD 0.25 ordinary

CFD

Opening a long position

2,000

47.2650 GBP

USD 0.25 ordinary

CFD

Reducing a short position

7,500

77.9456 USD

USD 0.25 ordinary

CFD

Reducing a short position

75,000

78.1656 USD

USD 0.25 ordinary

CFD

Reducing a short position

50,000

78.7457 USD

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

21 May 2014

Contact name:

Aadithya Rao and Yiannis Bardis

Telephone number:

+44(20) 7051 9046 / +44(20) 7774 7107

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERPGUAWAUPCGQG
Date   Source Headline
6th Jan 20207:00 amRNSLokelma approved in China for hyperkalaemia
2nd Jan 20203:00 pmRNSTotal Voting Rights
30th Dec 20197:00 amRNSUS FDA approved Lynparza for pancreatic cancer
23rd Dec 20197:00 amRNSTriple-combination approved in China for COPD
23rd Dec 20197:00 amRNSEnhertu (trastuzumab deruxtecan) approved in US
20th Dec 20197:00 amRNSAstraZeneca divests rights to Arimidex and Casodex
17th Dec 20196:06 pmRNSFDA panel backs Lynparza use for pancreatic cancer
16th Dec 20197:00 amRNSSeroquel rights agreement complete: Europe, Russia
12th Dec 20197:00 amRNSImfinzi approved in China for Stage III NSCLC
11th Dec 20191:00 pmRNSTrastuzumab deruxtecan achieves ORR of 60.9%
5th Dec 20197:00 amRNSLynparza approved in China for 1L BRCAm ovarian
3rd Dec 20197:00 amRNSAstraZeneca divests Seroquel rights: US and Canada
2nd Dec 20193:00 pmRNSBlock listing Interim Review
2nd Dec 20193:00 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSImfinzi granted FDA Priority Review for SCLC
21st Nov 20196:15 pmRNSCalquence approved in CLL in the US
15th Nov 20197:00 amRNSQtrilmet approved in the EU for treatment of T2D
14th Nov 20197:00 amRNSFDA accepts regulatory submission for selumetinib
12th Nov 20197:00 amRNSAnifrolumab demonstrated superiority in TULIP 2
11th Nov 20197:00 amRNSRoxadustat pooled analyses: no increased CV risk
8th Nov 20197:00 amRNSRoxadustat significantly increased haemoglobin
6th Nov 20192:10 pmRNSCalquence data to show improved progression-free
1st Nov 20193:00 pmRNSTotal Voting Rights
30th Oct 20197:00 amRNSAstraZeneca divests rights to Seroquel and
28th Oct 20193:31 pmRNSImfinzi and Imfinzi plus tremelimumab delayed
24th Oct 20197:00 amRNSAstraZeneca year-to-date and Q3 2019 results
21st Oct 20197:00 amRNSFarxiga approved in the US to reduce the risk of
17th Oct 20197:00 amRNSTrastuzumab deruxtecan granted FDA Priority Review
4th Oct 20193:04 pmRNSHolding(s) in Company
4th Oct 20193:00 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSFasenra approved in the US for self-administration
3rd Oct 20194:00 pmRNSDirector Declaration
1st Oct 20193:00 pmRNSTotal Voting Rights
1st Oct 20197:05 amRNSAstraZeneca divests rights for Losec to Cheplaphar
1st Oct 20197:00 amRNSUpdate on US regulatory review of PT010 in COPD
30th Sep 20193:30 pmRNSLynparza more than doubled the time without
30th Sep 20197:00 amRNSTagrisso is the only 1st-line treatment for EGFR-
30th Sep 20197:00 amRNSLynparza improved the time women lived without
23rd Sep 20197:00 amRNSQtrilmet recommended for approval in EU by CHMP
18th Sep 20197:00 amRNSAstraZeneca amends collaboration with Ironwood
9th Sep 20198:38 amRNSImfinzi is first immunotherapy to show both
4th Sep 20197:11 amRNSTagrisso approved in China as a 1st-line treatment
2nd Sep 20193:00 pmRNSTotal Voting Rights
2nd Sep 20197:05 amRNSBrilinta reduced the risk of cardiovascular events
2nd Sep 20197:00 amRNSDetailed results from Phase III DAPA-HF trial
29th Aug 20197:00 amRNSAnifrolumab Phase III trial meets primary endpoint
28th Aug 20197:05 amRNSFasenra granted US Orphan Drug Designation for
28th Aug 20197:00 amRNSBreztri Aerosphere Phase III ETHOS trial met
22nd Aug 20197:00 amRNSRoxadustat approved in China for the treatment of
22nd Aug 20197:00 amRNSAstraZeneca agrees to buy US FDA Priority Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.